candesartan has been researched along with Pulmonary Disease, Chronic Obstructive in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme randomized 7599 patients with symptomatic HF to receive candesartan or placebo." | 5.14 | Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. ( Granger, CB; Hawkins, NM; Maggioni, AP; McMurray, JJ; Michelson, EL; Ostergren, J; Petrie, MC; Pfeffer, MA; Pocock, SJ; Solomon, SD; Swedberg, K; Wang, D; Yusuf, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hawkins, NM | 1 |
| Wang, D | 1 |
| Petrie, MC | 1 |
| Pfeffer, MA | 1 |
| Swedberg, K | 1 |
| Granger, CB | 1 |
| Yusuf, S | 1 |
| Solomon, SD | 1 |
| Ostergren, J | 1 |
| Michelson, EL | 1 |
| Pocock, SJ | 1 |
| Maggioni, AP | 1 |
| McMurray, JJ | 1 |
1 trial available for candesartan and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme.
Topics: Aged; Benzimidazoles; Biphenyl Compounds; Bronchodilator Agents; Comorbidity; Female; Heart Failure; | 2010 |